Mary Halloran Ruhle
Psychiatric/Mental Health · Troy, NYNPI 1730236142
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 904 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 904 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $6K from 17 others
What the payments were for
- Food & beverage$19,942100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 220 | $4,708 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 96 | $2,276 |
| AbbVie | 102 | $2,232 |
| Alkermes, Inc. | 69 | $2,057 |
| Otsuka America Pharmaceutical, Inc. | 98 | $1,705 |
| Teva Pharmaceuticals USA, Inc. | 66 | $1,155 |
| Vanda Pharmaceuticals Inc. | 46 | $1,051 |
| Neurocrine Biosciences, Inc. | 43 | $926 |
| Axsome Therapeutics, Inc. | 34 | $891 |
| Neuronetics, Inc. | 15 | $569 |
| E.r. Squibb & Sons, L.L.C. | 27 | $448 |
| Corium, LLC | 12 | $406 |
| Lundbeck LLC | 23 | $400 |
| Bausch Health US, LLC | 18 | $331 |
| Supernus Pharmaceuticals, Inc. | 9 | $281 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $163 |
| Indivior Inc. | 7 | $119 |
| Ironshore Pharmaceuticals Inc. | 4 | $102 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Noven Therapeutics, LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$948
- LYBALVI$890
- SPRAVATO$823
- CAPLYTA$604
- NEUROSTAR TMS THERAPY SYSTEM$283
- Auvelity$248
- ARISTADA INITIO$237
- QELBREE$150
- INVEGA SUSTENNA$140
- Azstarys$123
- INGREZZA$112
How this compares
$19,942 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify AsimtufiiAripiprazole | 13 | $65,793 |
| Invega SustennaPaliperidone Palmitate | 15 | $49,993 |
| CaplytaLumateperone Tosylate | 16 | $30,307 |
| RexultiBrexpiprazole | 15 | $20,663 |
| VraylarCariprazine Hcl | 12 | $17,012 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $10,917 |
| Clozapine | 18 | $2,613 |
| Vilazodone Hcl | 17 | $2,215 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $2,097 |
| Olanzapine | 59 | $1,979 |
| Bupropion XlBupropion Hcl | 79 | $1,826 |
| Mirtazapine | 38 | $1,628 |
| Quetiapine Fumarate | 27 | $1,413 |
| Duloxetine Hcl | 54 | $783 |
| Lamotrigine | 22 | $689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $1,705 | $86,45628 claims |
| Johnson & JohnsonInvega Sustenna | $4,708 | $49,99315 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,276 | $30,30716 claims |
| AbbVieVraylar | $2,232 | $17,01212 claims |
| Axsome Therapeutics, Inc.Auvelity | $891 | $10,91711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Troy
- Laurie LavinTroy$18K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.